Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP; PREVENT-HD Investigators. Piazza G, et al. Among authors: hsia j. Circulation. 2023 Jun 20;147(25):1891-1901. doi: 10.1161/CIRCULATIONAHA.123.063901. Epub 2023 May 8. Circulation. 2023. PMID: 37154020 Free PMC article. Clinical Trial.
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators. Sabatine MS, et al. Among authors: hsia j. Circulation. 2007 Mar 27;115(12):1528-36. doi: 10.1161/CIRCULATIONAHA.106.649939. Epub 2007 Mar 19. Circulation. 2007. PMID: 17372173 Clinical Trial.
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Mora S, et al. Among authors: hsia j. Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22. Circulation. 2010. PMID: 20176986 Free PMC article. Clinical Trial.
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial.
Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Hsia J, et al. Vasc Med. 2021 Dec;26(6):608-612. doi: 10.1177/1358863X211017641. Epub 2021 Jun 3. Vasc Med. 2021. PMID: 34082620 Clinical Trial.
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, Mátyás L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Krantz MJ, et al. Among authors: hsia j. Eur Heart J. 2021 Oct 14;42(39):4040-4048. doi: 10.1093/eurheartj/ehab408. Eur Heart J. 2021. PMID: 34430972 Clinical Trial.
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI; HEP-COVID Investigators. Spyropoulos AC, et al. Among authors: hsia j. JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203. JAMA Intern Med. 2021. PMID: 34617959 Free PMC article. Clinical Trial.
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, Capell WH, Hsia J, Beckman JA, Brodmann M, Diaz R, Habertheuer P, Leeper NJ, Powell RJ, Sillesen H, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP. Hess CN, et al. Among authors: hsia j. Circulation. 2021 Dec 7;144(23):1831-1841. doi: 10.1161/CIRCULATIONAHA.121.055146. Epub 2021 Oct 12. Circulation. 2021. PMID: 34637332 Free article. Clinical Trial.
428 results